A retrospective study of interstitial lung disease due to EGFR tyrosine kinase inhibitor and immune checkpoint inhibitor

A retrospective study of interstitial lung disease due to EGFR tyrosine kinase inhibitor and immune checkpoint inhibitor - NEJ040

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034321

Enrollment

300

Registered

2018-10-01

Start date

2018-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.non-small cell lung cancer with EGFR mutations 2.To have treatment history using EGFR tyrosine kinase inhibitor and immune check poinnt inhibitor

Exclusion criteria

Exclusion criteria: non

Design outcomes

Primary

Measure	Time frame
Relationships between sequence/interval to use EGFR tyrosine kinase inhibitor and immune checkpoint inhibitor, and frequency/severity of interstitial lung disease	—

Countries

Japan

Contacts

Public ContactRyo Ko

Juntendo University Department of Respiratory Medicine

rkou@juntendo.ac.jp03-3813-3111

Outcome results